Enanta Pharmaceuticals (ENTA) revenue breakdown
By product, Royalty is the largest at 99% of fiscal 2023 revenue, growing 11% a year over 3 years.
Revenue by product
Fiscal years, as Enanta Pharmaceuticals reports them in its 10-K filings; fiscal 2023 total $79M.
| Products | 2016 | 2017 | 2018 | 2023 | Share |
|---|---|---|---|---|---|
| Royalty | $58M | $38M | $192M | $78M | 99% |
| License | — | — | — | $1M | 1% |
| Milestone | $30M | $65M | $15M | — | — |
| Revenue from Grants | $576,000 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ENTA.
Open ENTA in InvestinglyQuestions
Where does Enanta Pharmaceuticals make its money?
In fiscal 2023, by product: Royalty $78M, License $1M.
From Enanta Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.